Latin Manharlal Chat
BSE Prices delayed by 5 minutes...
     Prices as on Sep 21, 2018 - 3:59PM     
  ABB India 1433.95 [ -0.18% ]
  ACC 1541.65 [ -1.32% ]
  Axis Bank Ltd. 599.4 [ -1.61% ]
  Bajaj Auto Ltd. 2790.7 [ -0.16% ]
  Bank of Baroda 111.65 [ -4.00% ]
  Bharti Airtel 372.4 [ 0.73% ]
  Bharat Heavy Ele 71.5 [ -4.16% ]
  Britannia Ind. 5780.55 [ -2.95% ]
  Cipla 660.6 [ 0.17% ]
  Coal India 275.65 [ -1.75% ]
  Colgate Palm. 1106.75 [ -0.93% ]
  Dabur India 456.1 [ -2.07% ]
  DLF Ltd. 198.75 [ -1.27% ]
  Dr. Reddy's Labs 2562.9 [ -1.57% ]
  Grasim Inds. 1048.4 [ -1.75% ]
  HCL Technologies 1084.6 [ -0.25% ]
  HDFC 1835.25 [ 0.22% ]
  HDFC Bank 1968.85 [ 0.35% ]
  Hero MotoCorp 3165.7 [ 0.74% ]
  ICICI Bank 317.8 [ -0.95% ]
  IDFC L 44.65 [ -6.98% ]
  Indian Hotels Co 128.1 [ -0.31% ]
  IndusInd Bank 1761.7 [ -2.38% ]
  Infosys 706.3 [ -1.96% ]
  ITC Ltd. 303.75 [ 1.37% ]
  L&T 1331.75 [ -0.04% ]
  Lupin Ltd. 889.75 [ -2.12% ]
  Mahi. & Mahi 957.2 [ 1.05% ]
  MTNL 15.15 [ -3.19% ]
  Nestle India 9765.15 [ -3.82% ]
  NIIT Ltd. 86.1 [ -4.12% ]
  NMDC Ltd. 115.7 [ -1.99% ]
  NTPC 167.35 [ -1.03% ]
  ONGC 180.1 [ 1.95% ]
  Punj. NationlBak 72.8 [ -8.20% ]
  SBI 270.05 [ -0.50% ]
  Vedanta 229.7 [ -0.13% ]
  Shipping Corpn. 47.55 [ -4.33% ]
  Sun Pharma. 635.5 [ -1.82% ]
  Tata Chemicals 735.05 [ -0.57% ]
  Tata Motors Ltd. 250.2 [ -0.99% ]
  Tata Steel 624.55 [ 0.66% ]
  Tata Power Co. 72.8 [ -3.51% ]
  United Spirits 537.6 [ -4.12% ]
  Wipro Ltd 337.35 [ 1.38% ]

Company Information

Home » Market » Company Information

Alembic Pharmaceuticals Ltd.

Sep 21, 03:45
648.90 +10.25 (+ 1.60 %)
 
VOLUME : 22646
Prev. Close 638.65
Open Price 638.00
TODAY'S LOW / HIGH
609.70
 
 
 
654.00
Bid PRICE (QTY.) 650.10 (2)
Offer PRICE (Qty.) 0.00 (0)
52 WK LOW / HIGH
412.40
 
 
 
662.00
Sep 21, 03:48
654.25 +16.55 (+ 2.60 %)
 
VOLUME : 171702
Prev. Close 637.70
Open Price 633.15
TODAY'S LOW / HIGH
612.40
 
 
 
656.95
Bid PRICE (QTY.) 0.00 (0)
Offer PRICE (Qty.) 654.25 (2)
52 WK LOW / HIGH
414.40
 
 
 
664.00
Company Information Menu

Search Company

Market Cap. ( ₹ ) 12333.65 Cr. P/BV 5.56 Book Value ( ₹ ) 117.77
52 Week High/Low ( ₹ ) 664/414 FV/ML 2/1 P/E(X) 29.89
Bookclosure 27/07/2018 TTM EPS ( ₹ ) 23.15 Div Yield (%) 0.61
DIRECTOR'S REPORT
You can view full text of the latest Director's Report for the company.
Year End :2017-03 

Dear Member’s

The Directors have pleasure in presenting their 7th Annual Report together with the Audited Statement of Accounts for the year ended on 31st March, 2017.

1. Operations and State of Affairs of the Company:

(Rs. In Crores)

Stand Alone basis

Particulars

Consolidated Basis

2017

2016

For the year ended 31st March

2017

2016

634.84

988.24

Profit for the year before Interest, Depreciation and Tax

616.26

1,012.20

Adjusting therefrom:

2.23

2.37

Interest (net)

4.20

3.68

82.90

71.86

Depreciation

82.97

72.21

119.08

215.28

Provision for taxation

122.19

216.12

(2.13)

(0.41)

Share of Loss of Associates, Joint Venture, Non-controlling Interest & Other Comprehensive Income

(5.87)

(0.56)

428.50

698.33

Total Comprehensive Income

401.03

719.63

-

-

Share of Reserves in Associates & Joint Venture

-

(8.26)

Adding thereto:

657.69

338.37

Balance brought forward from previous year

713.62

381.26

1,088.32

1,037.10

The amount available is

1,116.69

1,101.30

Appropriating there from:

75.41

65.98

Dividend paid on Equity Shares during the year

75.41

65.98

15.35

13.43

Corporate Dividend tax paid during the year

15.35

13.43

300.00

300.00

Transfer to General Reserve

300.00

300.00

697.56

657.69

Balance carried forward to Balance Sheet

726.02

713.62

The break-up of consolidated sales including export incentives is as under:

(Rs. In Crores)

Particulars

F.Y. 2016-17

F.Y. 2015-16

Formulations

India

1,254.47

1,175.96

International

1,236.29

1,461.50

API

India

57.66

50.52

International

582.51

474.42

Total

3,130.93

3,162.40

The Company has prepared the Standalone and Consolidated Financial Statements in accordance with the Companies (Indian Accounting Standards) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013. The Company has adopted the Indian Accounting Standards (Ind AS) from 1st April, 2016. The comparative financial information of the Company for the year ended 31st March, 2016 have also been restated to comply with Ind AS.

2. Transfer to Reserves:

An amount of Rs.300 Crores from the net profits for the financial year under review is proposed to be carried to General Reserves.

3. Dividend:

Your Directors recommend Dividend on Equity Shares at Rs.4.00 per share (i.e. 200%) of face value RS.2/- per share for the financial year ended 31st March, 2017 as against Rs.4.00 per share (i.e. 200%) for the financial year ended 31st March, 2016.

4. Management Discussion and Analysis Report:

The Management Discussion and Analysis Report as required under Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is included in this Annual Report. Certain Statements in the said report may be forward looking. Many factors may affect the actual results, which could be different from what the Directors envisage in terms of the future performance and outlook.

5. Subsidiaries, Associates and Joint Venture:

In accordance with third proviso of Section 136(1) of the Companies Act, 2013, the Annual Report of the Company, containing therein its standalone and the consolidated financial statements has been placed on the website of the Company, www.alembicpharmaceuticals.com. Further, as per fourth proviso of the said section, audited annual accounts of each of the subsidiary companies have also been placed on the website of the Company, www.alembicpharmaceuticals. com. Shareholders interested in obtaining a physical copy of the audited annual accounts of the subsidiary companies may write to the Company Secretary at the Company’s registered office.

6. Directors:

In accordance with the provisions of the Companies Act, 2013 and the Articles of Association of the Company, Mr. Pranav Amin, Managing Director of the Company, will retire by rotation at the ensuing Annual General Meeting and is eligible for re-appointment.

7. Key Managerial Personnel:

Mr. Chirayu Amin, Executive Chairman & CEO, Mr. Pranav Amin, Managing Director, Mr. Shaunak Amin, Managing Director, Mr. R. K. Baheti, Director - Finance & CFO and Mr. Ajay Kumar Desai, Vice President - Finance & Company Secretary are Key Managerial Personnel of the Company.

8. Meetings of the Board:

Four (4) Board Meetings were held during the financial year ended 31st March, 2017. The details of the Board Meetings with regard to their dates and attendance of each of the Directors thereat have been provided in the Corporate Governance Report.

9. Independent Directors:

The Independent Directors of the Company have given the declaration to the Company that they meet the criteria of independence as provided in of Section 149(6) of the Companies Act, 2013.

10.Performance Evaluation:

Pursuant to the provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has carried out the annual performance evaluation of the Directors individually as well as evaluation of the working of the Board and of the Committees of the Board, by way of individual and collective feedback from Directors.

The following were the Evaluation Criteria:

(a) For Independent Directors:

- Knowledge and Skills

- Professional conduct

- Duties, Role and functions

(b) For Executive Directors:

- Performance as Team Leader/Member

- Evaluating Business Opportunity and analysis of Risk Reward Scenarios

- Key Set Goals and Achievements

- Professional Conduct and Integrity

- Sharing of Information with the Board

The Directors expressed their satisfaction with the evaluation process.

11.Audit Committee:

The Audit Committee consists of Independent Directors with Mr. Paresh Saraiya as Chairman, Mr. Pranav Parikh, Mr. Milin Mehta and Dr. Archana Hingorani as members. The Committee inter alia reviews the Internal Control System, Reports of Internal Auditors and Compliance of various regulations. The Committee also reviews the financial statements before they are placed before the Board.

12.Vigil Mechanism

Pursuant to the provisions of Section 177(9) & (10) of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a Vigil Mechanism or ‘Whistle Blower Policy’ for directors, employees and other stakeholders to report genuine concerns has been established. The same is also uploaded on the website of the Company.

13.Internal Control Systems:

The Company’s internal control procedures which includes internal financial controls, ensure compliance with various policies, practices and statutes and keeping in view the organization’s pace of growth and increasing complexity of operations. The internal auditors team carries out extensive audits throughout the year across all locations and across all functional areas and submits its reports to the Audit Committee of the Board of Directors.

14.Corporate Social Responsibility:

Alembic Group has been proactively carrying out CSR activities since more than fifty years. Alembic Group has established, nurtured and promoted various Non Profit Organisations focusing on three major areas - Education, Healthcare and Rural Development.

In compliance with requirements of Section 135 of the Companies Act, 2013, the Company has laid down a CSR Policy. The composition of the Committee, contents of CSR Policy and report on CSR activities carried out during the financial year ended 31st March, 2017 in the format prescribed under Rule 9 of the Companies (Corporate Social Responsibility Policy) Rules, 2014 is annexed herewith as Annexure A.

15.Policy on Nomination and Remuneration:

The contents of Nomination and Remuneration Policy of the Company prepared in accordance with the provisions of Section 178 of the Companies Act, 2013 and Regulation 19 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are provided in the Corporate Governance Report.

16.Related Party Transactions:

Related party transactions that were entered into during the financial year were on arm’s length basis and were in ordinary course of business. There are no materially significant related party transactions made by the Company which may have potential conflict with the interest of the Company.

There are no material related party transactions which are not in ordinary course of business or which are not on arm’s length basis and hence there is no information to be provided as required under Section 134(3)(h) of the Companies Act, 2013 read with Rule 8(2) of the Companies (Accounts) Rules, 2014.

The Board has approved a policy for related party transactions which has been uploaded on the Company’s website. The web-link as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is as under: http://www.alembicpharmaceuticals.com/wp-content/ uploads/2016/07/05APL-RPT-policy.pdf

17.Corporate Governance:

The Report on corporate governance as stipulated under Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 forms part of the Annual Report.

The requisite certificate from M/s. Samdani Shah & Kabra, Practising Company Secretaries confirming compliance with the conditions of corporate governance as stipulated under the aforesaid Schedule V is attached to the Report on Corporate Governance.

18.Fixed Deposits:

As on 31st March, 2017, there were unclaimed deposits amounting to Rs.0.07 Crore from 18 deposit holders which have been transferred to current liabilities. There has been no default in repayment of deposits or interest thereon. In F.Y. 2016-17, the Company has not accepted/renewed any deposits.

19.Listing of shares:

The Equity Shares of the Company are listed on the BSE Limited (BSE) with scrip code No. 533573 and on National Stock Exchange of India Limited (NSE) with scrip code of APLLTD. The Company confirms that the annual listing fees to both the stock exchanges for the financial year 2017-18 have been paid.

20.Loans, Guarantees or Investments:

Details of Loans granted, Guarantees given and Investments made during the year under review, covered under the provisions of Section 186 of the Companies Act, 2013 is annexed herewith as Annexure B.

21.Auditors:

(a) Statutory Auditors:

In compliance with the Companies (Audit and Auditors) Rules, 2014, M/s. K. S. Aiyar & Co., Chartered Accountants, has been appointed as Statutory Auditors of the Company till the conclusion of Annual General Meeting for the F. Y. 2018-19, as approved by the members at their 4th Annual General Meeting held on 28th July, 2014.

Further, pursuant to the requirement of Section 139 of the Companies Act, 2013, the appointment of Statutory Auditors is to be ratified by the members at every Annual General Meeting. Members are requested to ratify their appointment for the F. Y. 2017-18.

The Auditor’s Report for the financial year 2016-17 does not contain any qualification, reservation or adverse remark. The Auditor’s Report is enclosed with the financial statement in this Annual Report

(b) Secretarial Auditors:

The Board of Directors of the Company appointed M/s. Samdani Shah & Kabra, Practising Company Secretaries, Vadodara, to conduct Secretarial Audit for the F.Y. 2017-18.

The Secretarial Audit Report of M/s. Samdani Shah & Kabra, Practising Company Secretaries for the financial year ended 31st March, 2017, is annexed herewith as Annexure C.

The Secretarial Audit Report does not contain any qualification, reservation or adverse remark.

(c) Cost Auditors:

Mr. H. R. Kapadia, Cost Accountant, Vadodara, Cost Auditor of the Company has been appointed as Cost Auditor for conducting audit of the cost accounts maintained by the Company relating to Bulk Drugs and Formulations for the F.Y. 2017-18.

(d) Internal Auditors:

The Board of Directors appointed M/s. Ernst & Young LLP, Chartered Accountants as Internal Auditors of the Company for the F. Y. 2017-18.

22.Risk Management

The Company has voluntarily constituted Risk Management Committee and formulated Enterprise Risk Management Policy which functions as a guiding tool in fulfilling the management’s responsibility towards risk management. Major risks identified by the businesses and functions are systematically addressed through mitigating actions on a continuing basis. These are discussed at the meetings of the Risk Management Committee, Audit Committee and the Board of Directors of the Company.

23.Directors’ Responsibility Statement:

In terms of the provisions of Companies Act, 2013, the Directors state that:

(a) in preparation of the annual accounts for the financial year ended 31st March, 2017, the applicable accounting standards have been followed along with proper explanation relating to material departures;

(b) the directors have selected such accounting policies as listed in Note 2 to the financial statements and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give true and fair view of the state of affairs of the Company at the end of the financial year as on 31st March, 2017 and of the profit of the Company for that period;

(c) the directors have taken proper and sufficient care for maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

(d) the directors have prepared the annual accounts on a going concern basis; and

(e) the directors have laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.

(f) the directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

24.Material Changes:

There have been no material changes and commitments affecting the financial position of the Company since the close of financial year i.e. since 31st March, 2017. Further, it is hereby confirmed that there has been no change in the nature of business of the Company.

25.Extracts of Annual Return:

The extract of Annual Return required under Section 134(3(a) of the Companies Act, 2013 read with Rule 12(1) of the Companies (Management and Administration) Rules, 2014, is annexed herewith as Annexure D.

26.Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo:

The information required under Section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014, is annexed herewith as Annexure E.

27. Particulars of employees and related disclosures:

Disclosures pertaining to remuneration and other details as required under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, is annexed herewith as Annexure F.

A statement showing the names and other particulars of the employees drawing remuneration in excess of the limits set out in Rules 5(2) and 5(3) of the aforesaid Rules are provided in the Annual Report. The Annual Report is being sent to the members of the Company excluding the aforesaid information. The said information is available for inspection at the registered office of the Company during working hours and the same will be furnished on request in writing to the members.

28.Details of Unclaimed Suspense Account:

Disclosure pertaining to Unclaimed Suspense Account as required under Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is annexed herewith as Annexure G. The voting rights on the equity shares which are transferred to Unclaimed Suspense Account shall remain frozen till the rightful owner of such equity shares claims the shares.

On behalf of the Board of Directors,

Chirayu Amin

Chairman & CEO

3rd May, 2017

Alembic Pharmaceuticals Limited

Regd. Office: Alembic Road, Vadodara - 390 003

Tel: 0265-2280550 Fax: 0265-2282506

Web: www.alembicpharmaceuticals.com

Email Id: apl.investors@alembic.co.in

CIN: L24230GJ2010PLC061123